Sientra to Report First Quarter 2020 Financial Results on May 11, 2020

Rhea-AI Summary

Sientra, Inc. (NASDAQ: SIEN) announced it will release its financial results for Q1 2020 after market close on May 11, 2020. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results. Domestic callers can dial 844-464-3933, while international participants can reach 765-507-2612 using conference ID 3594402. The call will be webcast live on Sientra's Investor Relations website and archived for later access. Sientra focuses on medical aesthetics, offering advanced breast products and the miraDry system for sweat and odor treatment.

SANTA BARBARA, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020. Sientra will host a conference call to discuss financial results the same day at 5:00 p.m. Eastern Time.

The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 3594402.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

About Sientra
Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS^® breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2^® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM^® the #1 performing, preferred and recommended scar gel of plastic surgeons^(*). The Company’s miraDry Segment, comprises its miraDry^® system, which is approved for sale in over 40 international markets, and is the only non-surgical FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Contact
Investor Relations
805-679-8885

FAQ

When will Sientra release its Q1 2020 financial results?

Sientra will release its Q1 2020 financial results after market close on May 11, 2020.

What time is the conference call for Sientra's Q1 2020 financial results?

The conference call will take place at 5:00 p.m. ET on May 11, 2020.

How can I access the conference call for Sientra's financial results?

You can access the conference call by dialing 844-464-3933 for domestic callers or 765-507-2612 for international callers, using conference ID 3594402.

Will the conference call be available for later listening?

Yes, the conference call will be webcast live and archived on Sientra's Investor Relations website.

What areas does Sientra focus on in its business?

Sientra specializes in diversified medical aesthetics, with a focus on advanced breast products and non-surgical treatments for sweat and odor.